Notice for trastuzumab deruxtecan (AstraZeneca Pty Ltd)
Active ingredients
trastuzumab deruxtecan
Sponsor
Date of review outcome
Lapse date
Type
Provisional determination
Dosage form(s)
Powder for injection
Therapeutic area
Oncology